Welcome to our dedicated page for Telix Pharmaceut SEC filings (Ticker: TLPPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telix Pharmaceuticals Limited (TLPPF) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory submissions, with AI-powered tools to help interpret them. Telix Pharmaceuticals Limited is a foreign private issuer that furnishes current reports on Form 6-K and indicates that it files annual reports on Form 20-F. These filings connect U.S. investors to announcements first made to the Australian Securities Exchange.
Each Form 6-K cover page identifies an attached announcement or press release, typically labeled as Exhibit 99.1. Examples include “Telix JP Morgan Healthcare Conference 2026 Presentation,” “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” “ProstACT Global Study Status,” “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded,” and “CMS Grants Transitional Pass-Through Status for Gozellix.” The detailed content is contained in the exhibits, while the Form 6-K itself confirms the nature and title of each disclosure.
On this page, you can review Telix’s Form 6-K submissions as they appear in the SEC’s EDGAR system, with real-time updates as new filings are furnished. AI-generated summaries highlight the key points of lengthy documents, helping you quickly understand the focus of each announcement. You can also use this page to locate Telix Pharmaceuticals Limited’s annual Form 20-F filings when available, giving you a structured way to examine both periodic and event-driven disclosures associated with the TLPPF symbol.
Telix Pharmaceuticals Limited has appointed experienced life sciences executive David Gill as a Non-Executive Director as part of its board expansion and succession planning. His appointment is effective May 11, 2026, subject to grant of an Australian Director Identification number.
Gill is expected to become Chair in due course, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board as a Non-Executive Director. Telix also announced that Genevieve Ryan resigned as Company Secretary effective April 2, 2026, with Shomalin Naidoo appointed interim Company Secretary and primary ASX Listing Rule contact from the same date.
Telix Pharmaceuticals Group Chief Financial Officer Darren Charlton Smith exercised previously granted share rights into ordinary shares. On March 29, 2026, he converted 1,111 share rights into 1,111 ordinary shares at an exercise price of $0.00 per share. These share rights were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. Following the transaction, he directly holds 11,921 ordinary shares of Telix Pharmaceuticals Ltd, and the exercised share rights position has been fully used with no remaining derivative balance reported. No open-market sale occurred in this filing; it reflects a routine compensation-related option exercise that increases his direct share ownership.
Telix Pharmaceuticals’ Group Chief Medical Officer, Cade David Norman, has reported his existing equity interests in the company. He holds 373,133 Ordinary Shares directly, along with several derivative awards tied to Telix ordinary shares.
These include Performance Share Appreciation Rights over 78,189 underlying Ordinary Shares at A$4.9500 per share expiring on April 4, 2027, and 84,293 underlying Ordinary Shares at A$6.9000 per share expiring on December 21, 2027. He also holds Share Rights over 1,080 underlying Ordinary Shares expiring on March 31, 2028 and 11,486 underlying Ordinary Shares expiring on March 31, 2029. Footnotes state these awards were granted between April 2022 and March 2026, with vesting dates in 2025–2027 and that each Share Right represents the contingent right to receive one ordinary share, subject to continued employment and forfeiture if employment is terminated for cause.
Telix Pharmaceuticals Ltd Group Chief Financial Officer Darren Charlton Smith has filed an initial ownership report showing a mix of ordinary shares and equity awards. He holds 10,810 Ordinary Shares directly. He also holds Performance Share Appreciation Rights over 45,449 and 32,463 Ordinary Shares at an exercise price of 6.1500 (Australian Dollars) expiring on October 24, 2027, and over 88,497 Ordinary Shares at an exercise price of 6.9000 expiring on December 31, 2027. In addition, he holds Share Rights over 1,111 Ordinary Shares expiring March 31, 2028 and 14,741 Ordinary Shares expiring March 31, 2029. Footnotes state that the PSARs and certain Share Rights were granted between October 2022 and March 2026 and became, or will become, vested and exercisable based on continued service and testing after the audited calendar year 2026 financial results.
Telix Pharmaceuticals Ltd director Nelson Mark Alexander has filed an initial Form 3 reporting his existing shareholdings. The filing shows indirect beneficial ownership of 3,628,750 Ordinary Shares held through MAN Holdings Pty Ltd, acting as trustee for the Nelson Hybrid Trust, of which he is a director and shareholder. This filing records his current position rather than any new share purchase or sale.
Telix Pharmaceuticals Ltd Group Chief Operating Officer Darren Joel Patti filed an initial ownership report showing existing equity interests in the company. The filing lists 25,558 Ordinary Shares held directly and 804 American Depositary Receipts, each convertible into one ordinary share according to the footnotes.
It also discloses derivative awards over ordinary shares, including Performance Share Appreciation Rights over 15,826 shares at $4.9500 per share and 27,448 shares at $6.9000, both with future expiration dates. Share Rights cover an additional 15,000, 12,541, and 15,000 underlying ordinary shares at a $0.0000 exercise price, with vesting and exercisability tied to continued service and future testing of results. The report records holdings only and does not show new market purchases or sales.
Telix Pharmaceuticals Limited filed Amendment No. 1 to its Form 20-F for the year ended December 31, 2025 to correct broken or incorrect hyperlinks for several exhibits, including Exhibits 4.17, 4.18, 8.1, 11.1, 12.1, 12.2, 13.1 and 13.2.
The amendment also adds new certifications from the Principal Executive Officer and Principal Financial Officer as required for such amendments, while leaving all previously filed financial statements and other disclosures unchanged. The number of ordinary shares outstanding as of December 31, 2025 was 338,777,049.
Telix Pharmaceuticals Ltd director Marie Elizabeth McDonald has filed an initial ownership report on Form 3. The filing shows an indirect holding of 3,719 Ordinary Shares held through Netwealth Investments Limited as custodian. This is a disclosure of existing holdings rather than a new share purchase or sale.
Telix Pharmaceuticals Ltd director Jann Elizabeth Skinner has filed an initial ownership report showing a significant indirect stake in the company. The Form 3 discloses indirect ownership of 595,000 Ordinary Shares held through Forellan Pty Limited, where Ms. Skinner is the sole director and shareholder. This filing records her existing position rather than new share purchases or sales.
Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.
Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.